Overview
Rybelsus 14 mg contains Semaglutide, an oral GLP-1 receptor agonist used to improve glycemic control in adults with type 2 diabetes mellitus. It works by enhancing insulin secretion, reducing glucagon release, and slowing gastric emptying, which leads to better blood sugar control and weight management. Rybelsus is the first GLP-1 agonist available in tablet form, offering a convenient oral alternative to injectable therapies.





